SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

Abstract Neoadjuvant chemotherapy (NACT) represents a standard option for breast cancer. Unfortunately, about 55–80% of breast cancer patients do not have a favorable response to chemotherapy. Highly specific tumor biomarker that can predict the pathological response to neoadjuvant chemotherapy is l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weipeng Zhao, Linlin Sun, Xichuan Li, Jun Wang, Ye Zhu, Yan Jia, Zhongsheng Tong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fd1f65916da6499290144a7fb58996d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd1f65916da6499290144a7fb58996d1
record_format	dspace
spelling	oai:doaj.org-article:fd1f65916da6499290144a7fb58996d12021-12-02T14:53:43ZSCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer10.1038/s41598-021-88258-92045-2322https://doaj.org/article/fd1f65916da6499290144a7fb58996d12021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88258-9https://doaj.org/toc/2045-2322Abstract Neoadjuvant chemotherapy (NACT) represents a standard option for breast cancer. Unfortunately, about 55–80% of breast cancer patients do not have a favorable response to chemotherapy. Highly specific tumor biomarker that can predict the pathological response to neoadjuvant chemotherapy is lacking. Stearoyl-CoA desaturase 5 (SCD5) is an integral membrane protein of the endoplasmic reticulum that participates in lipid metabolism. Previous studies on the role of SCD5 in human cancers drew different conclusions. Therefore, the role of SCD5 in breast cancer remains unclear. Our study aims to understand its expression signature, prognosis value and correlation with pathological response to NACT in breast cancer using bioinformatics from public databases. Analysis of samples from public databases showed that SCD5 expression was down-regulated in some human cancers including breast cancer, and low expression of SCD5 was associated with more aggressive breast cancer phenotypes. Survival analysis revealed that SCD5 expression was related to prognosis in breast cancer. Integrated analysis of multiple public datasets indicated that SCD5 expression signature was associated with pathological response to NACT, particularly in TNBC. Based on functional enrichment analysis, the most affected biological functions in high SCD5-expressing breast cancer tissues were involved in negative regulation of cell cycle. Moreover, a significantly negative correlation between SCD5 expression and several cell cycle regulators was noted. Taken together, SCD5 was involved in the development and progression of breast cancer and might be a predictive biomarker for response to NACT. In conclusion, SCD5 could serve as a predictive biomarker of pathological response to NACT and play a carcinostatic role in breast cancer. These results provided us with clues to better understand SCD5 from the perspective of bioinformatics and highlighted the clinical importance of SCD5 in breast cancer, especially triple negative breast cancer (TNBC).Weipeng ZhaoLinlin SunXichuan LiJun WangYe ZhuYan JiaZhongsheng TongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Weipeng Zhao Linlin Sun Xichuan Li Jun Wang Ye Zhu Yan Jia Zhongsheng Tong SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
description	Abstract Neoadjuvant chemotherapy (NACT) represents a standard option for breast cancer. Unfortunately, about 55–80% of breast cancer patients do not have a favorable response to chemotherapy. Highly specific tumor biomarker that can predict the pathological response to neoadjuvant chemotherapy is lacking. Stearoyl-CoA desaturase 5 (SCD5) is an integral membrane protein of the endoplasmic reticulum that participates in lipid metabolism. Previous studies on the role of SCD5 in human cancers drew different conclusions. Therefore, the role of SCD5 in breast cancer remains unclear. Our study aims to understand its expression signature, prognosis value and correlation with pathological response to NACT in breast cancer using bioinformatics from public databases. Analysis of samples from public databases showed that SCD5 expression was down-regulated in some human cancers including breast cancer, and low expression of SCD5 was associated with more aggressive breast cancer phenotypes. Survival analysis revealed that SCD5 expression was related to prognosis in breast cancer. Integrated analysis of multiple public datasets indicated that SCD5 expression signature was associated with pathological response to NACT, particularly in TNBC. Based on functional enrichment analysis, the most affected biological functions in high SCD5-expressing breast cancer tissues were involved in negative regulation of cell cycle. Moreover, a significantly negative correlation between SCD5 expression and several cell cycle regulators was noted. Taken together, SCD5 was involved in the development and progression of breast cancer and might be a predictive biomarker for response to NACT. In conclusion, SCD5 could serve as a predictive biomarker of pathological response to NACT and play a carcinostatic role in breast cancer. These results provided us with clues to better understand SCD5 from the perspective of bioinformatics and highlighted the clinical importance of SCD5 in breast cancer, especially triple negative breast cancer (TNBC).
format	article
author	Weipeng Zhao Linlin Sun Xichuan Li Jun Wang Ye Zhu Yan Jia Zhongsheng Tong
author_facet	Weipeng Zhao Linlin Sun Xichuan Li Jun Wang Ye Zhu Yan Jia Zhongsheng Tong
author_sort	Weipeng Zhao
title	SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
title_short	SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
title_full	SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
title_fullStr	SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
title_full_unstemmed	SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
title_sort	scd5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/fd1f65916da6499290144a7fb58996d1
work_keys_str_mv	AT weipengzhao scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT linlinsun scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT xichuanli scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT junwang scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT yezhu scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT yanjia scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer AT zhongshengtong scd5expressioncorrelateswithprognosisandresponsetoneoadjuvantchemotherapyinbreastcancer
_version_	1718389426678136832

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

Ejemplares similares